#USA #healthcare safety #Bethlehem #B. Braun #Midazolam Injection

B. Braun Launches New Midazolam Injection

B. Braun Medical Inc., an esteemed leader in infusion therapy and pharmaceutical manufacturing, has announced an innovative addition to its product lineup: Midazolam in 0.8% Sodium Chloride Injection. This new offering emphasizes enhanced safety features and usability for healthcare professionals. Set to make its debut in the U.S. market, the product comes in preservative-free formulations, addressing crucial safety concerns in medical settings.

Product Specifications

The Midazolam Injection will be available in two specified strengths: 50 mg in 50 mL and 100 mg in 100 mL. Each of these formulations is packaged in IV bags that are free from DEHP, PVC, and natural rubber latex, thereby prioritizing both patient and environmental safety. This conscientious approach reflects B. Braun's determination to ensure that their medical products do not compromise the wellbeing of patients or healthcare providers.

Important Safety Updates

One of the most significant advancements in this new product is its 36-month shelf life. This longevity not only offers healthcare facilities increased flexibility in managing their inventory but also enables long-term storage solutions. Each IV bag features a 2D enhanced barcode containing essential information, including the National Drug Code (NDC) number, lot number, and expiration date. This upgrade aims to streamline workflows and diminish the risk of medication errors, a serious concern in healthcare environments.

Jeremy Greene, the Sr. Director of Marketing for IV Fluids and Pharma Injectables, emphasized the importance of the new product, stating, "Midazolam in 0.8% Sodium Chloride Injection marks another meaningful step in our commitment to delivering high-quality, patient-focused solutions." He further elaborated that the enhancements in formulation, barcode technology, and packaging specifications echo B. Braun's dedication to improving medication safety for both patients and clinicians.

Expanding the Portfolio

The launch of Midazolam Injection is a strategic addition to B. Braun's existing portfolio of essential injectable medications. By reinforcing its commitment to innovation and patient safety, B. Braun is positioning itself as a trusted partner for healthcare providers worldwide. This initiative aligns with the company's philosophy of continuously seeking ways to enhance patient outcomes through better product design and functionality.

With a penetrating focus on patient satisfaction, B. Braun strives to equip healthcare professionals with the tools they need to concentrate on what truly matters: patient care. The company has established itself as not just a product manufacturer but a forward-thinking partner in advancing healthcare standards. Their ongoing commitment to research and development emphasizes the need for safe and effective medical solutions in a rapidly evolving medical landscape.

About B. Braun

B. Braun Medical Inc. is headquartered in Bethlehem, Pennsylvania, and serves as a pivotal contributor to smart infusion therapy and pharmaceutical innovations. As part of the larger B. Braun Group, which employs over 64,000 individuals worldwide, the company consistently engages with healthcare professionals and partners to address critical healthcare challenges effectively. The corporate mission centers around Sharing Expertise®, facilitating knowledge exchange to improve healthcare quality while controlling costs.

In conclusion, the introduction of Midazolam in 0.8% Sodium Chloride Injection is more than just a product launch. It symbolizes B. Braun's unwavering commitment to better, safer healthcare solutions that directly support healthcare professionals in their quest for excellence in patient care.